Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt Promotes Damour to CEO

NEW YORK, March 11 -GeneProt announced today that it has promoted former CFO Bertrand Damour to the position of CEO, filling a position that was vacant for almost a year following founder and CEO Cedric Loiret-Bernal's departure last April.


The Geneva-based proteomics company also said it elected Damour to its board of directors.


Damour, who like Loiret-Bernal is a graduate of the Kellog School of Business at NorthwesternUniversity, had been serving as co-chair of GeneProt's operating committee since Loiret-Bernal left. Before joining GeneProt, Damour worked in international banking, most recently heading up JP Morgan's Investment Banking Risk Management group in London.


The company has faced tough times, and has widened its strategy lately from chasing big deals like the $84 million partnership it signed two years ago with Novartis, to a pursuit of smaller partnerships as well.


This change follows the company's decision last fall to lay off 20 employees and postpone a planned launch of a North Brunswick, NJ facility.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.